The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2020 Sep 9

PMID 32903476

Citations 99

Authors

Lauren A Callender

Michelle Curran

Stephanie M Bates

Maelle Mairesse

Julia Weigandt

Catherine J Betts

Affiliations

Soon will be listed here.

Abstract

Evidence from the global outbreak of SARS-CoV-2 has clearly demonstrated that individuals with pre-existing comorbidities are at a much greater risk of dying from COVID-19. This is of great concern for individuals living with these conditions, and a major challenge for global healthcare systems and biomedical research. Not all comorbidities confer the same risk, however, many affect the function of the immune system, which in turn directly impacts the response to COVID-19. Furthermore, the myriad of drugs prescribed for these comorbidities can also influence the progression of COVID-19 and limit additional treatment options available for COVID-19. Here, we review immune dysfunction in response to SARS-CoV-2 infection and the impact of pre-existing comorbidities on the development of COVID-19. We explore how underlying disease etiologies and common therapies used to treat these conditions exacerbate COVID-19 progression. Moreover, we discuss the long-term challenges associated with the use of both novel and repurposed therapies for the treatment of COVID-19 in patients with pre-existing comorbidities.

Citing Articles

In-silico evaluation of the T-cell based immune response against SARS-CoV-2 omicron variants.

Sharma S, Roy D, Cherian S Sci Rep. 2024; 14(1):25413.

PMID: 39455652 PMC: 11511884. DOI: 10.1038/s41598-024-75658-w.

COVID-19 risk factors and outcomes in individuals with stiff person syndrome spectrum disorders before and after omicron.

Afshar H, Simpson A, Taylor E, Miles A, Chen H, Newsome S Orphanet J Rare Dis. 2024; 19(1):356.

PMID: 39334235 PMC: 11428925. DOI: 10.1186/s13023-024-03357-w.

COVID-19 Recovery Time and Its Predictors among Hospitalized Patients in Designated Hospitals in the Madhesh Province of Nepal: A Multicentric Study.

Singh J, Acharya D, Gautam S, Neupane D, Bajgain B, Mishra R Healthcare (Basel). 2024; 12(17).

PMID: 39273716 PMC: 11395077. DOI: 10.3390/healthcare12171691.

A Machine Learning-Based Web Tool for the Severity Prediction of COVID-19.

Christodoulou A, Katsarou M, Emmanouil C, Gavrielatos M, Georgiou D, Tsolakou A BioTech (Basel). 2024; 13(3).

PMID: 39051337 PMC: 11270362. DOI: 10.3390/biotech13030022.

Convergence of inflammatory response: Salivary cytokine dynamics in coronavirus disease 2019 and periodontal disease.

Gupta S, Mohindra R, Ramola M, Kanta P, Singla M, Malhotra M J Indian Soc Periodontol. 2024; 28(1):113-121.

PMID: 38988958 PMC: 11232810. DOI: 10.4103/jisp.jisp_508_23.

References

Wu L, Wang N, Chang Y, Tian X, Na D, Zhang L . Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis. 2008; 13(10):1562-4. PMC: 2851497. DOI: 10.3201/eid1310.070576. View

Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y . Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020; 71(16):2027-2034. PMC: 7184337. DOI: 10.1093/cid/ciaa344. View

Qu J, Wu C, Li X, Zhang G, Jiang Z, Li X . Profile of Immunoglobulin G and IgM Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020; 71(16):2255-2258. PMC: 7197626. DOI: 10.1093/cid/ciaa489. View

Franceschi C, Campisi J . Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014; 69 Suppl 1:S4-9. DOI: 10.1093/gerona/glu057. View

Robbiani D, Gaebler C, Muecksch F, Lorenzi J, Wang Z, Cho A . Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020; 584(7821):437-442. PMC: 7442695. DOI: 10.1038/s41586-020-2456-9. View

Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P . Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002; 346(26):2039-46. DOI: 10.1056/NEJMoa012354. View

DiazGranados C, Dunning A, Kimmel M, Kirby D, Treanor J, Collins A . Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014; 371(7):635-45. DOI: 10.1056/NEJMoa1315727. View

Falagas M, Kompoti M . Obesity and infection. Lancet Infect Dis. 2006; 6(7):438-46. DOI: 10.1016/S1473-3099(06)70523-0. View

Alghamdi I, Hussain I, Almalki S, Alghamdi M, Alghamdi M, El-Sheemy M . The pattern of Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive epidemiological analysis of data from the Saudi Ministry of Health. Int J Gen Med. 2014; 7:417-23. PMC: 4149400. DOI: 10.2147/IJGM.S67061. View

10.

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H . Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020; 130(5):2620-2629. PMC: 7190990. DOI: 10.1172/JCI137244. View

11.

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

12.

Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L . Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study. Clin Infect Dis. 2020; 71(15):889-890. PMC: 7184514. DOI: 10.1093/cid/ciaa330. View

13.

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

14.

Klopfenstein T, Kadiane-Oussou N, Toko L, Royer P, Lepiller Q, Gendrin V . Features of anosmia in COVID-19. Med Mal Infect. 2020; 50(5):436-439. PMC: 7162775. DOI: 10.1016/j.medmal.2020.04.006. View

15.

Pearson-Stuttard J, Blundell S, Harris T, Cook D, Critchley J . Diabetes and infection: assessing the association with glycaemic control in population-based studies. Lancet Diabetes Endocrinol. 2015; 4(2):148-58. DOI: 10.1016/S2213-8587(15)00379-4. View

16.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

17.

Golay J, Ubiali G, Introna M . The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable activity against chronic lymphocytic leukemia B cells with CD20 antibodies. Haematologica. 2017; 102(10):e400-e403. PMC: 5622871. DOI: 10.3324/haematol.2017.169334. View

18.

Chen L, Li X, Chen M, Feng Y, Xiong C . The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020; 116(6):1097-1100. PMC: 7184507. DOI: 10.1093/cvr/cvaa078. View

19.

Schulze-Koops H . Lymphopenia and autoimmune diseases. Arthritis Res Ther. 2004; 6(4):178-80. PMC: 464928. DOI: 10.1186/ar1208. View

20.

Hashmi S, Ahmed M, Murad M, Litzow M, Adams R, Ball L . Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. Lancet Haematol. 2016; 3(1):e45-52. DOI: 10.1016/S2352-3026(15)00224-0. View